NCT06008652View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DR-0201 in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 26, 2023

Primary Completion Date

July 24, 2024

Study Completion Date

July 24, 2024

Conditions
Healthy Adult Volunteers
Interventions
DRUG

DR-0201

DR-0201 is a bi-specific antibody

DRUG

Placebo

Placebo

Trial Locations (1)

5000

Dren Investigational Site, Adelaide

Sponsors

Lead Sponsor

Dren Bio

Collaborators (1)

Novotech
All Listed Sponsors
collaborator

Novotech

UNKNOWN

lead

Dren Bio

INDUSTRY

NCT06008652 - A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DR-0201 in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter